Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection

Trial Profile

Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Last checked against ClinicalTrials.gov record.
    • 15 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top